Unrelated Umbilical Cord Blood Transplantation Using a TBI/FLAG Conditioning Regimen for Adults with Hematologic Malignancies  by Okada, Masaya et al.
Unrelated Umbilical Cord Blood Transplantation Using
a TBI/FLAG Conditioning Regimen for Adults with
Hematologic Malignancies
Masaya Okada,1,2 Yoshihiro Fujimori,2 Mahito Misawa,1,2 Shunro Kai,2,3 Toshiyuki Nakajima,1
Yoshiko Okikawa,1 Atsushi Satake,1 Hisayuki Itoi,1 Hiroyuki Takatsuka,1,2 Takeyoshi Itsukuma,2
Keisuke Nishioka,1 Hiroya Tamaki,1 Kazuhiro Ikegame,1 Hiroshi Hara,2,4 Hiroyasu Ogawa1,2
1Division of Hematology, Department of Internal Medicine, 2Laboratory of Cell Transplantation, Institute for
Advanced Medical Sciences, and 3Division of Blood Transfusion, Hyogo College of Medicine, Nishinomiya, Hyogo,
Japan; and 4Department of Internal Medicine, Uegahara Hospital, Nishinomiya, Hyogo, Japan
Correspondence and reprint requests: Yoshihiro Fujimori, MD, PhD, Laboratory of Cell Transplantation, Institute for
Advanced Medical Sciences, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo 663-8501, Japan
(e-mail: fuji-y@hyo-med.ac.jp).
Received October 4, 2007; accepted May 25, 2008
ABSTRACT
A combined chemotherapy regimen comprising fludarabine, cytosine arabinoside, and granulocyte colony-stimu-
lating factor (FLAG)has beenused in the treatment of relapsedor refractory leukemias.Wehere report 38patients
with hematologic malignancies who underwent single-unit cord blood transplantation (CBT) with a conditioning
regimen comprising 12-Gy total-body irradiation (TBI) and FLAG therapy (TBI/FLAG). Graft-versus-host dis-
ease (GVHD) prophylaxis consisted of tacrolimus or cyclosporin A and/or methotrexate. The median nucleated
cell dose was 2.43  107/kg (range: 1.96-3.55  107/kg). Of 34 evaluable recipients, the cumulative incidence of
donor engraftmentwas 97%.Themedian time to reach an absolute neutrophil count of 500/mLwas 23 days (range:
18-35 days). The median time to an untransfused platelet count of 50,000/mL was 45.5 days (range: 28-208 days).
Sixteen patients developed grades II-IV of acute GVHD. Fourteen patients were alive at a median follow-up of 46
months (range: 4-77months).The estimated event-free survival at 3 years for all patientswas 33.5%,with 72.7% in
the standard-risk group (n5 11) and 17.7% in the high-risk group (n5 27) (P5 .0075). These results showed that
this novel regimenwas well tolerated by patients and able to establish sustained donor cell engraftment, indicating
the feasibility of TBI/FLAG as a conditioning regimen for CBT in adults with hematologic malignancies.
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Umbilical cord blood transplantation (CBT) has in-
creasingly been performed as an alternative to human
leukocyte antigen (HLA)-matched sibling or unrelated
bone marrow transplantation (BMT) [1-3]. The advan-
tages of CBT in comparison to BMT include prompt
availability of cryopreserved cells, a less stringent re-
quirement for HLA-type matches between donors and
recipients, and a low risk of inducing severe graft-ver-
sus-host disease (GVHD). The major drawbacks of
CBT are slow hematopoietic recovery and a high inci-
dence of graft failure, mainly because of a small number896of progenitors being infused,which ismore pronounced
in adults with greater body weight [4]. Generally, the
overall outcome in adult CBT needs to be improved
in comparison to that in adult allogeneic BMT [2]. A
standard conditioning regimen with cyclophosphamide
and total-body irradiation (TBI) produces favorable re-
sults for BMT [5], but a standard conditioning regimen
for CBT has not yet been firmly established.
Intensive combination chemotherapy has
significantly improved the prognosis of patients with
hematologic malignancy [6]. FLAG therapy using flu-
darabine (Flu), cytosine arabinoside (Ara-C), and
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been shown to be effective against a variety of hemato-
logic malignancies, including high-risk acute myeloid
leukemias [7,8] and acute lymphoblastic leukemia [9].
The use of FLAG therapy for the treatment of leuke-
mias is based on the following arguments: (1) infusion
of fludarabine before Ara-C increases the accumula-
tion of the active metabolite ara-C triphosphate in
leukemic cells [10], (2) G-CSF shortens the duration
of neutropenia and reduces infection rates in leukemia
patients [11], and (3) G-CSF may sensitize leukemic
blasts to S-phase-specific Ara-C by recruiting quies-
cent cells into the cell cycle and increasing Ara-C
phosphorylation [12]. Thus, FLAG therapy was phar-
macokinetically designed to increase antileukemic
metabolites, and was intended to exert an efficient an-
tileukemic effect in the treatment of relapsed or refrac-
tory leukemias.
Fludarabine is highly immunosuppressive and
shown to be especially effective in a nonmyeloablative
preparative regimen for allogeneic stem cell transplan-
tation (SCT) [13]. Pawson et al. [14] used FLAG with
or without idarubicin as a reduced-intensity condition-
ing (RIC) regimen for second allogeneic peripheral
blood SCT in the treatment of relapsed leukemia
patients. Thus, FLAG therapy may act not only as an
effective antileukemic chemotherapy regimen, but
also as an efficient preparative regimen for SCT.
In the present study, we developed a new condition-
ing regimen consisting of FLAG therapy combined
with 12-GyTBI (TBI/FLAG).We performedCBTus-
ing this regimen in 38 adult patients with hematologic
malignancies in our single institution. Our results dem-
onstrated the feasibility of this TBI/FLAG as a novel
myeloablative preparative regimen for CBT.
PATIENTS AND METHODS
Eligibility
Patients were eligible if they were in a condition
requiring SCT but had no 6/6 or 5/6 allele HLA-
matched related donor or 6/6HLA-matched unrelated
donor available, or needed urgent SCT within 3
months. Patients receiving a transplant during the first
or second complete remission of leukemia or non-
Hodgkin’s lymphoma, or those who had refractory
anemia of myelodysplastic syndrome (MDS) were
placed in the standard-risk group. Patients in their
third or subsequent remission, relapse, or partial re-
mission with refractory leukemia and those with
chronic myelogenous leukemia (CML) beyond the
first chronic phase at the time of CBTwere considered
to be in the advanced phase of disease and were placed
in the high-risk group. Patients with diseases with
high-risk cytogenetics, such as acute lymphoblastic
leukemia (ALL) with t(9;22) and acute myelogenous
leukemia (AML) with –5, del(5q), 27, del(7) ordel(11), were also included in the high-risk group
[15]. This study was approved by the institutional re-
view board of Hyogo College of Medicine. All patients
provided written informed consent.
CB grafts
Appropriate cord blood (CB) was identified
through the Japan Cord Blood Bank Network
(JCBBN), which maintains information on the hold-
ings of 11 local CB banks in Japan [16]. In the first
19 patients, CB grafts were selected on the basis of
serologic matching at 4-6 of 6 HLA loci (class I
HLA-A and -B, and class II HLA-DR alleles) as deter-
mined by a standard complement-dependent micro-
lymphocytotoxicity test [17]. In the subsequent 19
patients, high-resolution DNA typing of class II
DRB1 alleles was used for selection of class II alleles
according to the availability of the high-resolution
class II data. CB grafts selected had a cryopreserved
cell dose of at least 2  107 nucleated cells (NC) per
kilogram of recipient body weight (NC/kg). Confir-
matory high-resolution DNA typing of class I HLA-
A and -B and class II DRB1 alleles was also performed
[18-20]. All CB used were single units and were not
depleted of T lymphocytes.
Preparative Regimen
The TBI/FLAG regimen comprised TBI (12 Gy),
Flu (150 mg/m2), Ara-C (10 g/m2), and G-CSF. TBI
was administered daily at 3 Gy for 4 days (day 210
to day27). Flu, Ara-C, and G-CSF were administered
daily for 5 days (day26 to22). Flu (30mg/m2) was ad-
ministered intravenously over 2 hours. Four hours
after the completion of Flu infusion, Ara-C (2 g/m2)
was administered intravenously over 2 hours. The
TBI/FLAG regimen was performed irrespective of
prior Ara-C treatment. G-CSF (300 mg/m2) was ad-
ministered subcutaneously. In the first 24 consecutive
patients, G-CSF was administered to all patients, but
in the subsequent 14 patients, the G-CSF administra-
tion was omitted in patients with lymphoid leukemias
and lymphomas (n5 7), because efficacy of G-CSF on
lymphoid malignancy is not firmly established.
GVHD Prophylaxis and Treatment
GVHD prophylaxis was tacrolimus (n 5 11) or
cyclosporin A (CsA) (n 5 1) alone during the years
2000 to 2002. Tacrolimus plus short-term methotrex-
ate (MTX) (n5 9) or CsA plus short-term MTX (n5
17) was used since August 2002. Administration of
tacrolimus (0.02 mg/kg/day) or CsA (3 mg/kg/day)
in a continuous infusion was started on day –1 and con-
tinued until the patient became tolerate to oral admin-
istration. Short-term MTX was administered at 10
mg/m2 on day 1 and 7 mg/m2 on days 3 and 6 [21]. Af-
ter neutrophil engraftment, and in the absence of acute
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10% per week starting at approximately day 35. Acute
GVHD was clinically diagnosed using the criteria of
Glucksberg et al. [22]. Grade II to IV aGVHD was
treated with methylprednisolone at 1-2 mg/kg/day.
Patients who survived for .100 days were analyzed
for chronic GVHD (cGVHD).
Supportive Care
Each patient was isolated in a laminar air-flow
room. Ciprofloxacin at 400 mg/day and fluconazole
at 300 mg/day were administered from day 214 until
neutrophil recovery. G-CSF at 300 mg/m2 was again
administered to all patients from day 5 until neutrophil
recovery. Acyclovir was administered at 750 mg/day
for 5 weeks after transplantation to prevent herpes
simplex virus infection. Ganciclovir 10 mg/kg was
administered in 2 divided doses from day 210 to day
23 as prophylaxis for cytomegalovirus (CMV) infec-
tion. Detection of CMV antigenemia was performed
using an immunoperoxidase-conjugated antibody,
HRP-C7, which binds to an immediate-early antigen
of CMV, pp65 antigen. After grafting, ganciclovir ad-
ministration was reinstituted in patients demonstrat-
ing positive CMV antigenemia.
Donor Chimerism Analysis
Donor chimerism was analyzed using marrow and/
or blood samples. Chimerism was determined by quan-
titative PCR analysis of informative short tandem re-
peat regions in the recipients and donors (STR-PCR)
[21,23]. DNAwas extracted frommarrow or blood cells
using a SepaGene isolation kit (Sankyo Pure Chemical,
Tokyo, Japan), and amplified with fluorescent PCR
primers (AmpFlSTR profiler PCR amplification kit;
Applied Biosystems, San Jose, CA). The fluorescent
PCR products were separated by capillary electropho-
resis using a 310 Genetic Analyzer (Applied Biosys-
tems). GeneScan software and GeneMapper software
(Applied Biosystems) were used to calculate the per-
centage of donor and recipient DNA.
Engraftment
Engraftment was considered to have occurred
when whole blood cell counts of absolute neutrophil
counts of .500/mL were obtained for 3 consecutive
days after transplantation, accompanied by the detec-
tion of donor chimerism. Graft failure was considered
to have occurred when peripheral and marrow hypo-
plasia were noted after transplantation, and donor
markers could not be detected by using cytogenetic
and/or molecular techniques.
Regimen-Related Toxicity (RRT) and
Transplantation-Related Mortality (TRM)
RRT, the nonhematologic toxicities directly caused
by a given preparative regimen by day 28, were ana-lyzed using Bearman’s criteria [24]. TRM was defined
as death without primary disease progression.
Statistical Analysis
The probability of event-free survival (EFS) was
estimated using the Kaplan-Meier method with Man-
tel-Cox log rank test. In this analysis, graft failure, re-
lapse, disease progression, and death were defined as
events. We used Cox proportional hazards models to
determine which independent patient-, disease- and
transplant-related variables predict EFS. We first fit-
ted univariable models, then all variables with P \
.10 were included in a multivariable model. Hazard ra-
tios were estimated with 95% confidence intervals.
Categoric variables were compared using the c2 test.
Values of P\ .05 were considered to be significant.
All statistical analyses were carried out with StatView
version 5.0 software (SAS Institute, Cary, NC).
RESULTS
Patient Characteristics
Thirty-eight patients underwent CBT with a TBI/
FLAG conditioning regimen between December 2000
and February 2007 at our institution. The median age
of the patients was 38.5 years (range: 16-52 years) and
the median weight was 58 kg (range: 39-81 kg). Details
of patients’ characteristics are listed in Table 1. Eleven
patients (29%) who were in first or second remission
were placed in the standard-risk group. The remaining
27 patients (71%), who were placed in the high-risk
group, include 14 in relapse or partial remission with
Table 1. Patient Characteristics
Number of patients 38
Sex (male/female) 20/18
Age (year); median
(range)
38.5 (16-52)
Disease
Standard-Risk
CR1/CR2
RA, CP
High-Risk
. CR3/.AP
HRC
High-Risk
Rel/Ref
AML 5 4 5
ALL 4 5 2
MLL 2 0 0
NHL 0 1 1
ATL 0 0 2
MDS 0 0 2
CML 0 3 0
CLL 0 0 2
Total 11 13 14
AML indicates acute myelogenous leukemia; ALL, acute lympho-
blastic leukemia; MLL, mixed-lineage leukemia; NHL, non-
Hodgkin lymphoma; ATL, adult T cell leukemia; MDS, myelo-
dysplastic syndrome; CML, chronic myelogenous leukemia;
CLL, chronic lymphocytic leukemia; CR1, CR2, CR3 first, sec-
ond, and third complete remission; RA, refractory anemia; CP,
chronic phase of CML, Rel, relapse; Ref, refactory disease; AP,
accelerated phase of CML; HRC, high-risk cytogenetics.
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mission or with high-risk cytogenetics (Table 1).
Graft Characteristics
The median number of nucleated cells infused was
2.43 107/kg body weight (range: 1.96-3.55 107/kg)
and that of CD341 cells was 0.87 105/kg body weight
(range: 0.24-3.98  105/kg) (Table 2). CB grafts were
primarily selected on the basis of serologic matching
at HLA-A, -B, and -DR alleles (n 5 19) or serologic
matching at HLA-A and -B and high-resolution DNA
typing of DRB1 alleles (n 5 19). Only 1 graft (2%) in
primary selection was 3 HLA mismatches. However,
confirmatory high-resolutionDNA typing of both class
I and class II alleles revealed that 12 (31%) of the CB
grafts had 3 or 4 mismatched antigens (Table 2).
Recovery of Peripheral Blood Cell Counts and
Engraftment
Four of 38 patients were not evaluated for donor
engraftment because of early death from sepsis (n 5 2)
(day 7, day 21) or bleeding (n 5 2) (days 17, 22).
Of 34 evaluable recipients, the cumulative incidence
of primary donor engraftment was 97% (33 patients)
as 1 patient experienced graft rejection with autolo-
gous marrow recovery. The median time for neutro-
phil recovery (.500/mL) was 23 days (range: 18-35
days; n5 33) (Figure 1A). All of these patients accom-
panied by donor chimerism by 86% to 100% using
STR-PCR analysis of bone marrow cells at approxi-
mately day 21. After neutrophil recovery, 6 patients
did not achieve subsequent reticulocyte recovery; 5 pa-
tients died between day 25 and day 100, and 1 patient
experienced relapse. The median time for reticulocyte
recovery (.1%) was 29 days (range: 25-57 days; n 5
27) (Figure 1B). Thereafter, 1 patient, who experi-
enced relapse, failed to achieve platelet recovery. The
Table 2. Graft Characteristics and GVHD Prophylaxis
Cord blood
Total cells (107/kg) 2.43 (1.96-3.55)
CD341 cells (105/kg) 0.87 (0.24-3.98)
HLA mismatch Primary* Confirmatory†
0/6 1 0
1/6 9 6
2/6 27 20
3/6 1 10
4/6 0 2
GVHD prophylaxis
CsA/CsA 1 sMTX 1/17
Tacrolimus/tacrolimus 1 sMTX 11/9
GVHD indicates graft-versus-host disease; CsA, cyclosporin A;
sMTX, short-term methotrexate.
*Primary HLA mismatches were detected on the basis of serological
HLA-A, -B, and -DR alleles (n5 19) or serologicHLA-A and -B and
high-resolution DRB1 alleles (n 5 19).
†ConfirmatoryHLAmismatches were detected on the basis of high-
resolution HLA -A, -B, and -DRB1 alleles.median time for platelet recovery (.50,000/mL) was
45.5 days (range: 28-208 days; n 5 26) (Figure 1C).
Early Organ Toxicity
Early organ toxicity caused by the TBI/FLAG pre-
parative regimen by day 28 was graded by the regimen-
related toxicity (RRT) grading system [24]. Toxicities
because of infection, bleeding, GVHD, and drugs
administered posttransplant were excluded from this
Figure 1. Neutrophil, reticulocyte, and platelet engraftment.
Kaplan-Meier estimates of the probability of achieving a neutrophil
count of .500/mL (A), a reticulocyte count of .1% (B), and an
untransfused platelet count of .50,000/mL (C).
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grade I hepatic toxicity in 7 patients, andGrade I gastro-
intestinal toxicity (diarrhea) in 11 patients. No patient
developed cardiac toxicity (electrocardiograph abnor-
mality), pulmonary toxicity (dyspnea), renal toxicity (in-
crease in creatinine), or bladder toxicity (haematuria).
Infection
Five patients developed sepsis, 6 pneumonia, 1 hu-
man herpesvirus-6 (HHV-6) encephalitis and 1 inter-
stitial pneumonitis. Reactivation of cytomegalovirus
was documented in 16 patients and gancyclovir was ad-
ministered. One of them developed fatal interstitial
pneumonitis because of CMV. No obvious fungemia
and invasive aspergillosis were observed.
GVHD
Twenty-eight patients who attained engraftment
and survived .40 days were evaluated for aGVHD.
The cumulative incidence of grade II-IV aGVHD
was 57% (16/28), with grades II, III, and IV occurring
in 7, 8, and 1 patients, respectively. Appearance of
aGVHD varied depending on GVHD prophylaxis
used. The incidence of grade II-IV aGVHD was
88% (n 5 8) when single agent (tacrolimus or CsA
alone) was used in 2000 to 2002, and it was significant
reduced (45%, n 5 20) when short-term MTX was
used in combination with tacrolimus or CsA after Au-
gust 2002 (P5 .04 by the c2 test). Chronic GVHD de-
veloped in 11 (41%) of 27 evaluable patients who
survived .100 days. Of the 11 patients, 8 patients de-
veloped limited cGVHD and 3 extended cGVHD.
Relapse
Overall, 11 patients (28.9%) relapsed after CBT.
Cumulative incidence of relapse is shown in Figure 2.
Of these patients, 10 were in the high-risk group (3
with AML, 1 with MDS, 3 with ALL, 2 with non-
Figure 2. Cumulative incidence of relapse estimated by Kaplan-
Meier method.Hodgkin lymphoma), and 1 was in the standard risk
group (1 with ALL).
Causes of Death
TRMwithin 100 days was 23.6% (9 of 38 patients).
The main cause of death was bleeding (pulmonary and
cerebral) in 2 cases, sepsis in 2, multiple organ failure
in 2, herpes simplex virus-6 encephalitis in 1, and
pneumonia in 2. One patient died of relapse within
100 days. The cause of death after 100 days was relapse
in 10 cases, sepsis in 1, pneumonia in 1, interstitial
pneumonitis in 1, and cGVHD in 1. TRM at day
365, which excluded primary disease progression,
was 34.2% (13 out of 38 patients).
Survival and Prognostic Factors
Fourteen out of 38 patients were alive at a median
follow-up of 46 months (range: 4-77 months). Three-
year EFS was 33.5% (Figure 3). Using Cox propor-
tional hazards models, sex, weight, HLA match
(primary and confirmatory), cell dose, GVHDprophy-
laxis, and the presence of grade II-IV GVHD had no
apparent effect on EFS (Table 3). In contrast, age
and disease status at transplantation had significant
impacts on EFS in both univariable and multivariable
analysis (Table 3). Kaplan-Meier estimates indicated
that patients who were 42 years old or younger
(n 5 26) showed significantly better survival (39.8%)
than those who were older than 42 years (n 5 12)
(19.4%) (P 5 .0422) (Figure 4). Regarding the disease
status at transplantation, EFS was 72.7% in the stan-
dard risk group (n 5 11) and 17.7% in the high-risk
group (n 5 27) (P 5 .0075) (Figure 5). As the number
of patients included in this study is small, the results
shown above should be interpreted with caution.
DISCUSSION
Intensified chemotherapy can be effective in the
treatment of chemotherapy-sensitive malignant
Figure 3. Kaplan-Meier estimates of EFS in CBT (n 5 38).
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derived partly from the antileukemic effect of myeloa-
blative therapy and partly from a graft-versus-leuke-
mia effect of donor immune cells on the residual
leukemia. Transplantation using CB cells as alterna-
tive to the bone marrow cells or peripheral blood cells
has increasingly been performed for the treatment of
hematologic malignancies [1-3]. However, a standard
preparative conditioning regimen has not been firmly
Table 3. Risk Factors for Event-Free Survival (EFS) after CBT
Factors
Hazard
Ratio
95% Confidential
Interval P-Value
Univariate analysis
Sex 0.881 0.394-1.966 .7568
Age .42 2.325 1.007-5.493 .0481
Weight 1.016 0.969-1.064 .5168
Disease status:
high risk
4.604 1.356-15.634 .0143
Cell dose: total cells 0.696 0.239-2.064 .5140
HLA match
(primary)*
0.885 0.458-1.708 .7152
HLA match
(confirmatory)†
1.022 0.666-1.567 .9218
GVHD prophylaxis
CsA vs tacrolimus:
CsA
0.701 0.301-1.585 0.3939
MTX 1 vs 2: 1 0.738 0.322-1.691 0.4730
Grade II-IV
acuteGVHD
0.688 0.215-2.200 0.5282
Multivariate analysis
Age .42 2.828 1.140-7.091 0.0250
Disease status:
high-risk
5.245 1.505-18.281 0.0093
GVHD indicates graft-versus-host disease; CsA, cyclosporin A;
MTX, methotrexate.
*Primary HLA matches were detected on the basis of serological
HLA-A, -B, and -DR alleles (n 5 19) or serologic HLA-A and -B
and high-resolution DRB1 alleles (n 5 19).
†Confirmatory HLA matches were detected on the basis of high-
resolution HLA -A, -B, and -DRB1 alleles.
Figure 4. EFS in relation to age. Kaplan-Meier estimates of EFS in
patients 42 years old or younger (n5 26) and older than 42 (n5 12)
(P 5 .0422).established. We here report the results of CBT using
a new myeloablative regimen, TBI/FLAG.
In the present study, we used 12-Gy TBI (in 4 frac-
tions) andFLAGcomprising10g/m2Ara-C,150mg/m2
Flu, and G-CSF. High-dose Ara-C has been found
to be effective in the treatment of myeloid and lym-
phoid leukaemia patients with poor prognoses
[25,26]. A conditioning regimen using TBI and
high cumulative doses of Ara-C (24 or 36 g/m2)
achieves a lower relapse rate [27]. However, a signif-
icant proportion of allogeneic or autologous BMT
patients who received high cumulative doses of Ara-
C (36 g/m2) has been reported to die early as a result
of toxicity [28]. The incidence of pulmonary complica-
tions, including interstitial pneumonia and obvious
infection, and the risk of pulmonary toxicity, increases
with age. These results suggest that the use of high cu-
mulative doses of Ara-C (36 g/m2) for conditioning
should be avoided. Tomonari et al. [29] carried out
a preliminary trial in which 5 patients who received
CBT were conditioned with 24 g/m2 Ara-C, 90 mg/
m2 Flu, and 12-Gy TBI. All patients showed favorable
prognosis. Furthermore, Takahashi et al. [30] reported
that a conditioning regimen comprising 12-Gy TBI,
Ara-C (12 g/m2), cyclophosphamide (120 mg/kg),
and G-CSF produced very good outcomes. Thus, ap-
propriate doses of Ara-C may be effective as part of
a preparative regimen. In the TBI/FLAG regimen
used in this study, the total dose of Ara-C was limited
to 10 g/m2, and its activity was pharmacokinetically
augmented by concomitant use of fludarabine [10].
This preparative regimen was found to be associated
with minimal early RRT within 28 days and without
any enhancement of later pulmonary or other life-
threatening toxicities.
In CBT, the incidence of grade II-IV aGVHD has
been reported to be 40% to 70% [31,32]. It was 58% in
this study. When single-agent (tacrolimus or CsA
alone) was used in 2000 to 2002, the incidence of grade
Figure 5. EFS in relation to disease status. Kaplan-Meier estimates
of EFS in standard-risk patients (n5 11) and high-risk patients (n5
27) (P 5 .0075).
902 M. Okada et al.II-IV aGVHD was high (88%, n 5 8), but it was
significantly reduced to 45% (n 5 20) when short-
term MTX was used together with tacrolimus or
CsA after August 2002. However, the combined
use of MTX for GVHD prophylaxis did not result in
the improvement of the survival rate in our analysis
(Table 3). Rather, the disease status had the strongest
impact on the survival rate (Table 3). Our patients’ re-
sponse to steroid therapy was generally good for those
with grade II and III aGVHD (data not shown).
Rocha et al. [33] reported the results of CBT on 98
patients in multicenter analysis, which showed 36% of
2-year survival. Laughlin et al. [2] also reported multi-
centric analysis of CBT including 150 patients that
showed 26% of 3-year survival. In single-institution
studies of adult CBT, Long et al. [34] reported
3-year survival of 19%of57patients,whereasTakahashi
et al. [30] showed 2-year survival of 74% of 113
patients. In our single-institution study using a
single-conditioning regimen, 3-year EFS was 33.5%
(Figure 3). Cell dose of CB graft is known to be one
of the critical factors that affect EFS in CBT [31], but
we did not find this is to be the case in our analysis
(Table 3). This is probably because we used CB with
relatively large number of cells, with the median cell
number of 2.43  107 cells/kg. We found that patients
older than 42 showed poor EFS (Figure 4), and this
FLAG/TBI conditioned CBT is favorable to those
who are 42 or younger. Regarding disease status and
survival, 3-year EFS was 72.7% in the standard risk
group (n 5 11) and 17.7% in the high-risk group
(n 5 27) (P5 .0075) (Figure 5). The EFS of 17.7% in
the high-risk group in our study is comparable to pre-
viously reported rates of 15% to 20% [2].The results of
the present study are encouraging because standard-
risk patients had 72.7% survival, which is comparable
to that seen in standard-risk patients receiving alloge-
neic BMT or peripheral blood stem cell transplanta-
tion from HLA-matched donors [35]. This may
indicate that CBT has almost the same efficacy as
BMT in standard-risk patients. Although the finding
must be confirmed in a larger scale study, our study
suggests that CBT following conditioning with the
TBI/FLAG regimen may be a reasonable option for
adults with hematologic malignancies.
The results presented above show that CBT with
a TBI/FLAG preparative regimen was well tolerated
without significant RRT, and offered sustained donor
cell engraftment. Patients who are 42 years old or youn-
ger and in standard riskmay obtain a favorable outcome
in this TBI/FLAG regimen. Further studies are needed
to optimize this procedure to establish an effective
treatment modality for hematologic malignancies.
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